We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Caution Advised When Using Vasopressin Septic Shock

By HospiMedica staff writers
Posted on 02 Jan 2008
Vasopressin should be used with great caution for the treatment of hypotension in septic shock, according to a new international study.

Researchers at the Washington University School of Medicine (St. More...
Louis, MI, USA) and other institutions in Iceland and Switzerland studied 32 pigs that were anesthetized, mechanically ventilated, and randomly assigned to one of four groups: Group S (sepsis) and group SV (sepsis and vasopressin) were exposed to fecal peritonitis; Group C and group V were non-septic controls. After 240 minutes, both septic groups were resuscitated with intravenous fluids; after 300 minutes, groups V and SV received intravenous vasopressin. Regional blood flow was measured in the hepatic and renal arteries, the portal vein, and the celiac trunk using ultrasonic transit time flowmetry. Microcirculatory blood flow was measured in the liver, kidney, and pancreas using laser Doppler flowmetry.

The researchers found that in septic shock, vasopressin decreased blood flow by 58% in the portal vein within an hour, and even after three hours the reduction stood at 45%. Blood flow in the liver, however, remained unchanged. The investigation also revealed that increased urine output did not necessarily reflect increased renal blood flow, and therefore may not be a useful indicator of the effects of a particular treatment. The study was published online on December 13, 2007, in the open access journal Critical Care.

"Vasopressin caused marked redistribution of splanchnic regional and microcirculatory blood flow, including a significant decrease in portal, pancreatic and renal blood flows, while hepatic artery flow remained virtually unchanged,” explained lead author Dr Vladimir Krejci, M.D., of the department of anesthesiology at Washington University medical school, and colleagues.

Vasopressin, a peptide hormone, is being developed as a new therapy for the hemodynamic support of septic shock and vasodilatory shock due to systemic inflammatory response syndrome, and has previously been shown in animal models to increase blood pressure in septic shock that fails to respond to catecholamines. However, the safety of vasopressin treatment in humans with septic shock is yet to be proven.


Related Links:
Washington University School of Medicine

Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
LED Surgical Lamp
ACEMST35/57
Endoscopy Display
E190
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Surgical Techniques

view channel
Image: The fiber in the brain implant is less than half a millimeter thick (Photo courtesy of Peter Aagaard Brixen)

Brain Implant Records Neural Signals and Delivers Precise Medication

Neurological diseases such as epilepsy involve complex interactions across multiple layers of the brain, yet current implants can typically stimulate or record activity from only a single point.... Read more

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.